文献类型：期刊文献

英文题名：Successful treatment with bortezomib in combination with dexamethasone in a middle-aged male with idiopathic multicentric Castleman's disease: A case report

作者：Li, Hongling[1];He, Yang[1,2];Wang, Yongying[1,3];Xu, Mengwei[4]

第一作者：Li, Hongling

通信作者：Li, HL[1]

机构：[1]Gansu Prov Hosp, Dept Oncol, 204 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China;[2]Ningxia Med Univ, Coll Clin Med, Yinchuan, Peoples R China;[3]Gansu Univ Chinese Med, Coll Clin Med 1, Lanzhou, Peoples R China;[4]Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian, Peoples R China

第一机构：Gansu Prov Hosp, Dept Oncol, 204 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Oncol, 204 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China.

年份：2024

卷号：19

期号：1

外文期刊名：OPEN MEDICINE

收录：;Scopus(收录号：2-s2.0-85183782331);WOS:【SCI-EXPANDED(收录号:WOS:001145920600001)】；

基金：This study was supported by grants from the Hospital Internal Scientific Research Foundation of Gansu Province Hospital (No. 19SYPYA-3, 20YF8WA096)

语种：英文

外文关键词：idiopathic multicentric Castleman disease; bortezomib; salvage strategy; refractory; case report

摘要：Multicentric Castleman disease (MCD) is a heterogeneous, life-threatening disease. A subgroup of HIV-negative and HHV-8-negative MCD is defined as idiopathic MCD (iMCD) with a poor prognosis. Here we report an unusual case of a 47-year-old male patient with iMCD who experienced multiple treatment regimens such as chemotherapy, immunomodulatory therapy, and targeted therapy, all of which were considered ineffective. Subsequently, he was started on bortezomib in combination with dexamethasone for six cycles and he was in complete remission. The patient has survived nearly 13 years to date - the longest survival of any iMCD patient treated with bortezomib in combination with dexamethasone. Bortezomib combined with dexamethasone may be an effective salvage strategy for severe and refractory iMCD.